^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Pancreatic Cancer
    Drug:MRTX1133 (KRAS G12D inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

    Excerpt:
    ...- Histologically confirmed diagnosis of a solid tumor malignancy harboring KRAS G12D mutation in tumor tissue or ctDNA....
    Trial ID:
    NCT05737706
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mirati Therapeutics Press Release
    Title:

    MIRATI THERAPEUTICS REPORTS INVESTIGATIONAL ADAGRASIB (MRTX849) PRELIMINARY DATA DEMONSTRATING TOLERABILITY AND DURABLE ANTI-TUMOR ACTIVITY AS WELL AS INITIAL MRTX1133 PRECLINICAL DATA

    Published date:
    10/25/2020
    Excerpt:
    MRTX1133, the Company's potent, selective and reversible inhibitor of KRAS G12D...MRTX1133 demonstrated tumor regression in multiple in vivo tumor models, including pancreatic and colorectal cancers.